Switzerland-based immuno-transcriptomics company Novigenix SA said its blood-based colorectal cancer test delivered encouraging results.
Researchers studied 282 subjects: 78 had colorectal cancer, 65 had advanced adenomas, 39 had other cancers and 100 had no colorectal lesions. The test had a specificity of 88 percent and a sensitivity of 83 percent.
The company is hoping to build off this trial with a prospective colon cancer clinical validation trial that it plans to enroll more than 1,600 subjects into. The results from that trial could be used to validate the company's newly formed noninvasive colon cancer test.